Common Meds Linked to Reduced Immunotherapy Benefit in Lung Cancer

Exposure to proton pump inhibitors (PPIs) was associated with worse progression-free survival (PFS) and overall survival (OS) in patients with locally advanced non-small cell lung cancer (NSCLC) who were treated with durvalumab. The findings, presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, suggest a potential negative interaction between these commonly prescribed medications and immune checkpoint inhibitors.

The retrospective analysis examined data from 102 patients enrolled in the PACIFIC trial, which evaluated durvalumab as consolidation therapy after chemoradiotherapy for unresectable stage III NSCLC. Researchers found that patients who were taking PPIs at the time of randomization had a significantly lower median PFS compared to those not taking PPIs. Specifically, median PFS was 13.4 months for non-PPI users versus 7.6 months for PPI users.

Similarly, overall survival was also negatively impacted. The median OS for non-PPI users was 32.6 months, while for PPI users it was 18.3 months. These differences were statistically significant, indicating a potential clinical relevance. The study's lead author, Dr. Rina J. Hui of the Royal Prince Alfred Hospital in Sydney, Australia, presented these results, highlighting the need for further investigation into this association.

While the study was retrospective and involved a relatively small sample size, the observed trends warrant attention. PPIs are widely used to manage acid-related gastrointestinal disorders, making them a common co-medication for many cancer patients. The mechanism behind this potential interaction is not fully understood but may involve PPIs altering the tumor microenvironment or affecting immune cell function in ways that diminish the efficacy of immunotherapy. Further prospective studies are recommended to confirm these findings and explore potential clinical implications, such as reconsidering PPI use in patients undergoing immunotherapy.